11 June 2025
EMA/CAT/223455/2025
Human Medicines Division

Committee for Advanced Therapies (CAT)

Minutes of the meeting on 14-16 May 2025

Chair: Ilona Reischl; Vice-Chair: Kieran Breen

Health and safety information

In accordance with the Agency's health and safety policy, delegates are to be briefed on health, safety and emergency information and procedures prior to the start of the meeting.

Disclaimers

Some of the information contained in these minutes is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also vary during the course of the review. Additional details on some of these procedures will be published in the CAT meeting reports once the procedures are finalised.

Of note, these minutes are a working document primarily designed for CAT members and the work the Committee undertakes.

Note on access to documents

Some documents mentioned in the minutes cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to on-going procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006).

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000 An agency of the European Union

Table of contents

1. Introduction

1.1. Welcome and declarations of interest of members, alternates and experts

The Chairperson opened the meeting by welcoming all participants. The meeting was held in person with some members attending remotely.

In accordance with the Agency's policy on handling of declarations of interests of scientific committees' members and experts, based on the declarations of interest submitted by the Committee members, alternates and experts and on the topics in the agenda of the current meeting, the Committee Secretariat announced the restricted involvement of some Committee members, alternates and experts for concerned agenda topics.

Participants were asked to declare any changes, omissions or errors to their declared interests and/or additional restrictions concerning the matters for discussion. No new or additional interests or restrictions were declared. Restrictions applicable to this meeting are captured in the List of participants included in the minutes.

Discussions, deliberations and voting took place in full respect of the restricted involvement of Committee members and experts in line with the relevant provisions of the Rules of Procedure. All decisions, recommendations and advice were agreed by consensus, unless otherwise specified.

The Chair thanked the departing members and alternates for their contribution to the work of the Committee.

The EMA Secretariat announced the names of the Committee members who delegated their vote via proxy and the Committee members who received such proxy.

1.2. Adoption of agenda

The CAT agenda for 14-16 May 2025 meeting was adopted.

1.3. Adoption of the minutes

The CAT minutes of 14-16 April 2025 meeting were adopted.

2. Evaluation of ATMPs

2.1. Opinions

2.1.1. Aucatzyl - Obecabtagene autoleucel - PRIME - Orphan - EMEA/H/C/005907

Autolus GmbH; Treatment of patients with relapsed or refractory B cell precursor acute lymphoblastic leukaemia (ALL)

Scope: Opinion

Action: for adoption

List of outstanding issues adopted on 21.03.2025. List of questions adopted on 19.07.2024.

The Rapporteurs presented the outcome of the assessment of the responses to the list of outstanding issues. CAT discussed the post-authorisation commitments and the conditions for the conditional marketing authorisation and specific obligations. CAT discussed the product information.

CAT adopted a positive opinion recommending the granting of a conditional marketing authorisation to Aucatzyl.

2.2. Oral explanations

No items

2.3. Day 180 list of outstanding issues

2.3.1. Lifileucel - EMEA/H/C/004741

Treatment of unresectable or metastatic melanoma

Scope: Day 180 list of outstanding issues

Action: for adoption

List of questions adopted on 06.12.2024.

The CAT Rapporteurs presented the outcome of the assessment of the responses to the list of questions. Feedback was provided from the BWP discussion

The list of outstanding questions was adopted and the response timetable was agreed.

2.4. Day 120 list of questions

No items

2.5. Day 80 assessment reports

No items

2.6. Update on ongoing initial applications

No items

2.7. New applications

No items

2.8. Withdrawal of initial marketing authorisation application

No items

2.9. Re-examination of initial application procedures under Article 9(2) of Regulation No. 726/2004

No items

2.10. GMP and GCP inspections requests

No items

2.11. Type II variations and variations of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008

2.11.1. Yescarta - Axicabtagene ciloleucel - Orphan - EMEA/H/C/004480/II/0085

Kite Pharma EU B.V.

Rapporteur: Jan Mueller-Berghaus

Scope: Clinical, opinion

Submission of the final report from study KT-US-482-0147 (ZUMA-26). This is a Prospective, Noninterventional, Clinical Efficacy Study Investigating and Analysing the Impact of Tumour Cd19 Antigen Expression and Density on Response to Axicabtagene Ciloleucel Treatment Using a Quantitative Flow Cytometry Method.

Action: for adoption

Request for supplementary information adopted on 21.02.2025.

The outcome of the assessment was presented. The opinion was adopted.

2.11.2. Tecartus; Yescarta - Axicabtagene ciloleucel; Brexucabtagene autoleucel - Orphan - EMEA/H/C/WS2771

Kite Pharma EU B.V.

Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Karin Erneholm

Scope: Safety, PRAC led, request for supplementary information

Submission of an updated RMP version 4.3 for Tecartus and version 11.1 for Yescarta following the PRAC recommendation for the secondary malignancy of T-cell origin signal (EPITT no: 20040), and of a PASS protocol for a framework for the sampling and testing of secondary malignancies of T-cell origin.

Action: for adoption

Request for supplementary information adopted on 24.01.2025.

The second request for supplementary information was adopted.

2.11.3. Kymriah - Tisagenlecleucel - Orphan - EMA/VR/0000258240

Novartis Europharm Limited

Rapporteur: Rune Kjeken

Scope: Quality, opinion

Action: for adoption

The opinion was adopted.

2.11.4. Casgevy - Exagamglogene autotemcel - Orphan - EMA/VR/0000258214

Vertex Pharmaceuticals (Ireland) Limited

Rapporteur: Jan Mueller-Berghaus

Scope: Clinical, request for supplementary information

Update of section 5.3 of the SmPC in order to update non-clinical information and remove existing wording on off-target editing based on (1) Results of in silico analysis to nominate genetic variants and (2) Interim study report presenting results from genotyping of subjects and off-target editing in drug product from subjects in clinical Studies 111 and 121. In addition, the MAH took the opportunity to make editorial changes to the PI.

Action: for adoption

The Rapporteur presented the outcome of the assessment. CAT agreed that a warning statement related to the off target finding should be included in SmPC section 4.4. The request for supplementary information was adopted.

2.11.5. CARVYKTI - Ciltacabtagene autoleucel - Orphan - EMA/VR/0000258113

Janssen-Cilag International NV

Rapporteur: Jan Mueller-Berghaus

Scope: Quality, request for supplementary information

Action: for adoption

The request for supplementary information was adopted.

2.11.6. Tecartus - Brexucabtagene autoleucel - Orphan - EMA/VR/0000257524

Kite Pharma EU B.V.

Rapporteur: Jan Mueller-Berghaus

Scope: Clinical, opinion

Submission of the 57-month follow-up results from study ZUMA-3 (KTE-C19-103) listed as a Specific Obligation in the Annex II of the Product Information. This is a phase 1/2 open-label study evaluating the safety and efficacy of brexucabtagene autoleucel in adult participants with relapsed/refractory B-precursor acute lymphoblastic leukeamia (r/r ALL). The Annex II is updated accordingly.

Action: for adoption

The opinion was adopted.

2.11.7. Abecma - Idecabtagene vicleucel - Orphan - EMA/VR/0000249089

Bristol-Myers Squibb Pharma EEIG

Rapporteur: Rune Kjeken

Scope: Quality, request for supplementary information

Action: for adoption

Request for supplementary information adopted on 16.04.2025.

The second request for supplementary information was adopted.

2.11.8. Ebvallo - Tabelecleucel - Orphan - EMA/VR/0000245074

Pierre Fabre Medicament

Rapporteur: Egbert Flory

Scope: Quality, opinion

Action: for adoption

The opinion was adopted.

2.11.9. Hemgenix - etranacogene dezaparvovec - Orphan - EMA/VR/0000258413

CSL Behring GmbH

Rapporteur: Silke Dorner

Scope: Quality, opinion

Action: for adoption

The opinion was adopted.

2.12. Extension applications

No items

2.13. Other Post-Authorisation Activities

2.13.1. Ebvallo - Tabelecleucel - Orphan - EMA/PAM/0000258195

Pierre Fabre Medicament

Rapporteur: Egbert Flory

Scope: PAM, opinion

Action: for adoption

The Rapporteur's assessment report was adopted.

2.13.2. Ebvallo - Tabelecleucel - Orphan - EMA/S/0000249324

Pierre Fabre Medicament

Rapporteur: Egbert Flory

Scope: Annual reassessment, request for supplementary information

Action: for adoption

The request for supplementary information was adopted.

2.13.3. ROCTAVIAN - Valoctocogene roxaparvovec - Orphan - EMA/R/0000250212

BioMarin International Limited

Rapporteur: Violaine Closson Carella

Scope: Renewal, request for supplementary information

Action: for adoption

The request for supplementary information was adopted.

2.14. Companion diagnostics - initial consultation

No items

2.15. Companion diagnostics – Follow-up consultation

No items

3. Certification of ATMPs

Information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

3.1. Opinion

No items

3.2. Day 60 Evaluation Reports

No items

3.3. New Applications

No items

4. Scientific Recommendation on Classification of ATMPs

Timetable:

-Start of the procedure:	19.05.2025
-EMA Coordinator's draft report:	28.05.2025
-CAT Coordinator's comments:	04.06.2025
-Revised scientific recommendation:	06.06.2025
-CAT's discussion of scientific recommendation:	13.06.2025

4.1. New requests – Appointment of CAT Coordinator

4.1.1. Replication defective SV40 vector encoding for human proinsulin

Treatment of type 1 diabetes

Scope: Nomination of CAT coordinator

Action: for adoption

The CAT coordinator was appointed.

4.1.2. Anitocabtagene autoleucel

Treatment of patients with multiple myeloma

Scope: Nomination of CAT coordinator

Action: for adoption

The CAT coordinator was appointed.

4.2. Day 30 ATMP scientific recommendation

4.2.1. Human oocyte cytoplasma

For use in case of low human egg quality in in vitro fertilisation (IVF)

Scope: ATMP scientific recommendation

Action: for adoption

CAT discussed the classification report. CAT secretariat to send the draft scientific recommendation to the European Commission for comments by 02.06.2025.

4.2.2. Selected autologous Tumour-Infiltrating Lymphocytes (TILs) isolated from tumour tissue, lymph node metastases, or peripheral blood, expanded, activated

Treatment of advanced or metastatic solid tumours

Scope: ATMP scientific recommendation

Action: for adoption

CAT discussed the classification report. CAT secretariat to send the draft scientific recommendation to the European Commission for comments by 02.06.2025.

4.2.3. Autologous T cells ex vivo transduced with LVV encoding a CAR that recognises BCMA

Treatment of relapsed or refractory form of plasmocytic myeloma (RRMM)

Scope: ATMP scientific recommendation

Action: for adoption

CAT discussed the classification report. CAT secretariat to send the draft scientific recommendation to the European Commission for comments by 02.06.2025.

4.3. Day 60 revised scientific recommendation (following list of questions)

No items

4.4. Finalisation of procedure

4.4.1. Allogeneic T cells genetically modified ex vivo using CRISPR/Cas9 to express an anti-CD19 chimeric antigen receptor

Treatment of frontotemporal dementia (FTD) in adults who have a mutation in the GRN or chromosome 9 open reading frame 72 (C9orf72) genes

Scope: European Commission raised no comments. ATMP scientific recommendation

Action: for adoption

The classification report was adopted. The product does fulfil the definitions of a gene therapy medicinal product and a somatic cell therapy medicinal product and is therefore classified as a gene therapy medicinal product as provided in Article 2(5) of Regulation (EC) No. 1394/2007.

4.4.2. Induced pluripotent stem cell (iPSC)-derived photoreceptor precursor cells

Treatment of primary photoreceptor disease

Scope: European Commission raised no comments. ATMP scientific recommendation

Action: for adoption

The classification report was adopted. The product does fulfil the definition of a tissue engineered product as provided in Article 2(1) of Regulation (EC) No. 1394/2007.

4.4.3. Messenger mRNA encoding the human Dynein Axonemal Intermediate Chain 1 (DNAI1) protein

Treatment of primary ciliary dyskinesia caused by mutations in the DNAI1 gene

Scope: European Commission raised no comments. ATMP scientific recommendation

Action: for adoption

The classification report was adopted. The product does fulfil the definition of a gene therapy medicinal product as provided in Article 2(1) of Regulation (EC) No. 1394/2007.

4.4.4. Messenger mRNA encoding the cystic fibrosis transmembrane conductance regulator (CFTCR) protein

Treatment of cystic fibrosis

Scope: European Commission raised no comments. ATMP scientific recommendation

Action: for adoption

The classification report was adopted. The product does fulfil the definition of a gene therapy medicinal product as provided in Article 2(1) of Regulation (EC) No. 1394/2007.

4.4.5. Allogeneic genetically modified T-cells expressing two chimeric antigen receptors (CARs) targeting the human CD19 and CD70 proteins

Treatment of autoimmune diseases

Scope: European Commission raised no comments. ATMP scientific recommendation

Action: for adoption

The classification report was adopted. The product does fulfil the definitions of a gene therapy medicinal product and a somatic cell therapy medicinal product and is therefore classified as a gene therapy medicinal product as provided in Article 2(5) of Regulation (EC) No. 1394/2007.

4.4.6. Autologous tumour-derived dendritic cells

Prevention of relapses and metastasis of non-small cell lung carcinoma (NSCLC)

Scope: European Commission raised no comments. ATMP scientific recommendation

Action: for adoption

The classification report was adopted. On basis of the information provided by the applicant demonstrating that the enzymatic digestion is not changing relevant characteristics of the dendritic cells, CAT concluded that the product does not fulfil the definition of an advanced therapy medicinal product as provided in Article 2(1) of Regulation (EC) No. 1394/2007.

4.4.7. Genetically modified porcine heart

Intended for cardiac xenotransplantation to human patients with end-stage heart failure

Scope: ATMP scientific recommendation

Action: for adoption

The adoption of the report was postponed.

4.5. Follow-up and guidance

No items

5. Scientific Advice

Information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

5.1. New requests - appointment of CAT Rapporteurs

5.1.1. Ongoing scientific advice procedures - Appointment of CAT Peer Reviewers

Timetable:

- Start of procedure at SAWP:	05-08.05.2025
- Appointment of CAT Peer Reviewers:	14-16.05.2025
- SAWP first reports:	26.05.2025
- CAT Peer Reviewer comments (NC & C):	30.05.2025
- CAT Peer Reviewer comments (Q):	04.06.2025
- Discussion at SAWP:	02-05.06.2025
- Discussion at CAT and feedback to SAWP:	11-13.06.2025

5.1.2. Scientific advice procedures starting at the next SAWP meeting

Timetable:

- Start of procedure at SAWP:	02-05.06.2025
- Appointment of CAT Peer Reviewers:	11-13.06.2025
- SAWP first reports:	30.06.2025
- CAT Peer Reviewer comments (NC & C):	04.07.2025
- CAT Peer Reviewer comments (Q):	09.07.2025
- Discussion at SAWP:	07-10.07.2025
- Discussion at CAT and feedback to SAWP:	16-18.07.2025

5.2. Procedures discussed at SAWP – 1st reports, D40 JRs, LoIs

5.3. Finalisation of D70 procedures – feedback from the discussion meeting

5.4. Final Advice Letters for procedures finalised the previous month

6. Pre-Authorisation Activities

Information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

6.1. Paediatric investigation plans

No items

6.2. ITF briefing meetings in the field of ATMPs

No items

6.3. Priority Medicines (PRIME) – Eligibility requests

6.3.1. Month 0 - Start of the procedure

Timetable for assessment:	
Procedure start:	05-08.05.2025
SAWP recommendation:	05.06.2025
CAT recommendation:	13.06.2025
CHMP adoption of report and final recommendation:	19.06.2025

6.3.2. Month 1 – Discussion of eligibility

6.3.3. Month 2 – Recommendation of eligibility

No items

6.3.4. Ongoing support

No items

7. Organisational, regulatory and methodological matters

7.1. Mandate and organisation of the CAT

7.1.1. CAT membership

The chair thanked Anthony Samuel (alternate for Malta) and Katarina Kollarova (member for Slovakia) for their contributions to the work of the Committee

7.1.2. Vote by proxy

Liga Kunrade gave a proxy to Suzana Vidic to vote on behalf of Latvia during the entire meeting.

Dariusz Sladowski gave a proxy to Violaine Closson-Carela to vote on behalf of Poland during the entire meeting.

7.1.3. CAT Strategic Review & Learning meeting (SRLM) under the Danish presidency

CAT: Martin Bronislaw Oleksiewicz

Scope: Preparation for the meeting

Action: for information

CAT discussed agenda topics for the SRLM meeting that will take place on 29-30.10.2025 in Copenhagen. The meeting will include a half-day joint session with COMP.

7.1.4. CAT Strategic Review & Learning meeting (SRLM) under the Polish presidency

CAT: Dariusz Sladowski

Scope: Oral feedback from the meeting

Action: for information

Dariusz Sladowski provided a short feedback from the discussions at the Polish SRLM. The chair thanked him and the Polish team for organising the meeting.

7.2. Coordination with EMA Scientific Committees

No items

7.3. Coordination with EMA Working Parties/Working Groups/Drafting Groups

7.3.1. BWP/CAT Learning on Claims for New Active Substance (NAS) status for ATMPs

Rapporteur/Coordinator: Sean Barry, Ilona Reischl

Scope: BWP/CAT learning on assessment of NAS claims for ATMPs

Action: for discussion

CAT noted the progress in the development of this BWP/CAT learning for adoption during the June CAT meeting.

7.4. Cooperation with the EU regulatory network

No items

7.5. Cooperation with international regulators

7.5.1. ATMP cluster teleconference with US-FDA, Health Canada, PMDA (Japan) and Swissmedic

CAT: Ilona Reischl

Scope: Agenda topics for the teleconference of 26.06.2025

Action: for information

CAT made some suggestions for discussion at the June ATMP cluster TC

7.6. CAT work plan

No items

7.7. Planning and reporting

No items

7.8. Others

7.8.1. Richard Slayman Clinical Xenotransplant Workshop 31.05.2025 – 01.06.2025

Scope: Nomination of EMA/CAT representative to the workshop

Action: for action

CAT nominated Dr Antonia Godehardt (PEI) as EMA/CAT representative at the xenotransplantation workshop.

7.8.2. EMA survey: exploring the role of Patient Preference Studies in the Benefit/Risk assessment

Scope: Presentation to the committee

Action: for discussion

CAT was informed that the EMA survey will be sent to all committee members on 19.05.2025, for completion by 09.06.2025. All members were asked to complete the short

survey (no specific expertise is needed) and circulate the survey to the assessors in their agencies. EMA will report back from the survey when all data have been analysed.

7.8.3. American Society for gene and cell therapy (ASGCT) - Fireside chat: European Regulation and the future of Advanced Therapies

CAT: Ilona Reischl

Scope: Feedback from the fireside chat (14.05.2025)

Action: for information

Ilona Reischl gave a short oral feedback from the fireside chat at ASGCT.

8. Any other business

No items

9. List of participants

List of participants including any restrictions with respect to involvement of members/alternates/experts following evaluation of declared interests for the 14-16 May 2025 CAT meeting, which was held in-person.

An asterisk (*) after the role, in the second column, signals that the member/alternate attended remotely. Additional experts participated in (part of) the meeting, either in person or remotely.

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Ilona Reischl	Chair	Austria	No restrictions applicable to this meeting	
Silke Dorner	Member	Austria	No interests declared	
Claire Beuneu	Member	Belgium	No interests declared	
Olga Kholmanskikh	Alternate	Belgium	No interests declared	
Rozalina Kulaksazova	Member	Bulgaria	No interests declared	
Petra Sokol	Alternate	Croatia	No interests declared	
Rafaella Pontou	Member	Cyprus	No interests declared	
Eva Kolouchová*	Member	Czechia	No interests declared	
Radka Nejezchlebová	Alternate	Czechia	No interests declared	

Martin Oleksiewicz	Member	Denmark	No interests declared	
Johanne Juhl Korsbaek*	Alternate	Denmark	No restrictions applicable to this meeting	
Toivo Maimets	Member	Estonia	No restrictions applicable to this meeting	
Pille Saalik*	Alternate	Estonia	No interests declared	
Heli Suila	Member	Finland	No interests declared	
Violaine Closson Carella	Member	France	No interests declared	
Jean-Michel Race*	Alternate	France		
Jan Mueller-Berghaus	Member (CHMP co-opted member)	Germany	No interests declared	
Maria Gazouli	Member	Greece		
Angeliki Rompoti*	Alternate	Greece	No restrictions applicable to this meeting	
Viola Bardoczy*	Member	Hungary	No restrictions applicable to this meeting	
Agnes Zotter	Alternate	Hungary		
Péter Zsolt Fekete	Member	Iceland	No interests declared	
Joseph De Courcey	Member	Ireland	No interests declared	
Richard Carroll*	Alternate	Ireland	No interests declared	
Concetta Quintarelli	Member	Italy	No restrictions applicable to this meeting	
Barbara Bonamassa*	Alternate	Italy	No interests declared	
Liga Kunrade*	Alternate	Latvia	No restrictions applicable to this meeting	
Vilma Perikaite	Member (CHMP member)	Lithuania	No restrictions applicable to this meeting	
Alessia Pochesci	Member	Luxembourg	No restrictions applicable to this meeting	
John J. Borg	Member (CHMP member)	Malta	No interests declared	
Emmely de Vries	Member	Netherlands	No interests declared	
Berendina Maria (Tineke) van den Hoorn	Alternate	Netherlands	No interests declared	

Rune Kjeken	Member	Norway	No restrictions applicable to this meeting	
Ole Henrik Myrdal*	Alternate	Norway	No interests declared	
Dariusz Sladowski*	Member	Poland	No restrictions applicable to this meeting	
Maria Isabel Borba Vieira	Member	Portugal	No interests declared	
Denisa Marilena Margina	Member	Romania	No restrictions applicable to this meeting	
Liviu Nitulescu*	Alternate	Romania	No restrictions applicable to this meeting	
Margareta Fogelová	Alternate	Slovakia	No interests declared	
Suzana Vidic	Member	Slovenia	No restrictions applicable to this meeting	
Sol Ruiz*	Member (CHMP co-opted member)	Spain	No interests declared	
Marcos Timón*	Alternate (to CHMP representative)	Spain	No interests declared	
Maria Luttgen	Member	Sweden	No restrictions applicable to this meeting	
Charlotte Anderberg	Alternate	Sweden	No interests declared	
Bernd Gansbacher	Alternate	Clinicians' Representative	No interests declared	
Paolo Gasparini	Member	Clinicians' Representative	No restrictions applicable to this meeting	
Alessandra Renieri*	Alternate	Clinicians' Representative	No restrictions applicable to this meeting	
Kerstin Sollerbrant Melefors	Member	Patients' Representative	No restrictions applicable to this meeting	
Mencia de Lemus Belmonte	Alternate	Patients' Representative	No interests declared	
Kieran Breen	Member (Vice-Chair)	Patients' Representative	No restrictions applicable to this meeting	
Torbjörn Callréus	Expert	Malta	No interests declared	
Jenny (Zhiyi) You	Expert	Denmark	No interests declared	
Boje Kvorning Pires Ehmsen	Expert	Denmark	No interests declared	
Jolien de Groot	Expert	Netherlands	No interests declared	

Annemarie den Harder	Expert	Netherlands	No restrictions applicable to this meeting	
Lucas Mevius	Expert	Netherlands	No interests declared	
Teresa Llacer Delicado	Expert	Spain	No interests declared	
A representative from the European Commission attended the meeting				
Meeting run with support from relevant EMA staff. Experts' declared interests were evaluated against the agenda topics or activities they participated in.				

Date of next CAT meeting:

11-13 June 2025

10. Explanatory notes

The Notes give a brief explanation of relevant agenda items and should be read in conjunction with the agenda.

For a list of acronyms and abbreviations, see:

List of abbreviations used in EMA human medicines scientific committees and CMDh documents, and in relation to EMA's regulatory activities

Evaluation of ATMPs (section 2)

This section lists applications for marketing authorisations of new Advanced Therapy Medicinal Products (ATMPs) that are to be discussed by the Committee. It also lists Post-authorisation activities (section 2.11-2.13) and any ATMP related inspection requests (section 2.14).

New applications (sections 2.1. to 2.9.)

Section 2.1 is for ATMPs nearing the end of the evaluation and for which the CAT is expected to adopt a draft **opinion** at this meeting on whether marketing authorisation should be granted. Once adopted, the CAT opinion is transmitted to the CHMP for final adoption. The CHMP opinion will be forwarded to the European Commission for a final legally binding decision valid throughout the EU. More information on the evaluation of ATMPs can be found here.

The other items in the section are listed depending on the stage of the evaluation, which is shown graphically below:



The assessment of an application for a new medicine takes up to 210 'active' days. This active evaluation time is interrupted by at least one 'clock-stop' during which time the applicant prepares the answers to questions from the CAT. The clock stop happens after day 120 and may also happen after day 180, when the CAT has adopted respectively a **Day 120 list of questions** (section 2.4) or a List of outstanding issues to be addressed by the company, which is listed in the agenda under sections 2.7 (**Ongoing evaluation procedures** (section 2.3). Section 2.6 also includes the CAT discussions at any other timepoint of the evaluation procedure of new applications.

Oral explanation (section 2.2.)

Prior to adoption of the CAT opinion, marketing authorisation applicants are normally invited to the CAT plenary meeting to address questions raised by the Committee.

Oral explanations normally relate to ongoing applications, but they can also relate to any other issue for which the CAT would like to discuss with company representatives in person.

New applications (section 2.7.)

In this section, information is included on upcoming marketing authorisation applications for ATMPs, as well as information on appointment of Rapporteurs for new ATMP applications.

Withdrawal of applications (section 2.8.)

This section includes information on marketing authorisation applications that are withdrawn by the applicant. Applicants may decide to withdraw applications at any stage during the assessment and a CAT opinion will therefore not be issued. Withdrawals are included in the agenda for information or discussion, as necessary.

Re-examination procedures (new applications) under article 9(2) of regulation no 726/2004 (section 2.9.)

This section lists applications for new marketing authorisation for ATMPs for which the applicant has requested a re-examination of the opinion previously issued by the CHMP. Similar to the initial evaluation of a marketing authorisation of an ATMP, CAT will adopt a draft re-examination opinion, which is transmitted to the CHMP for final adoption.

GMP and GCP Inspections Issues (section 2.10.)

This section lists inspections that are undertaken for ATMPs. Inspections are carried out by regulatory agencies to ensure that marketing authorisation holders comply with their obligations. Inspection can relate to good manufacturing practice (GMP), good clinical practice (GCP), good laboratory practice (GLP) or good pharmacovigilance practice (GVP).

Post-authorisation activities (section 2.11-2.13.)

Section 2.11 lists type II variations, including extension of indication applications and re-examination procedures for type II variations for which the applicant has requested re-examination of the opinion previously issued by the CHMP. Section 2.12 list extension application according to Annex I of Reg. 1234/2008 and section 2.13 includes all other post-authorisation activities concerning authorised ATMPs that are not covered elsewhere in the agenda such as post-authorisation measures, annual reassessments, 5-year renewals, supply shortages, qualify defects. Issues that have been discussed at the previous meeting of the PRAC, the EMA's committee responsible for evaluating and monitoring safety issues for medicines, will also be included here.

Companion diagnostics (section 2.14-2.15)

This section lists applications for initial and follow-on consultation of companion diagnostics.

Certification of ATMPs (section 3)

This section includes the scientific evaluation by the CAT of quality and non-clinical data that small and medium-sized enterprises have generated at any stage of the ATMP development process. More information on the ATMP certification procedure can be found here.

Scientific Recommendation on Classification of ATMPs (Section 4)

This section includes the scientific recommendation by the CAT on whether medicines based on genes, cells or tissues meet the scientific criteria that define ATMPs. More information on the ATMP classification procedure, including the outcomes of finalised classifications, can be found here.

Scientific Advice (section 5)

This section includes all scientific advice given to companies during the development of an ATMP. Information related to the number of ATMP related scientific advices discussed by CAT can be found in the CAT Monthly reports. Further information on SAWP can be found here.

Pre-Authorisation (section 6)

Paediatric Investigation Plan (PIP)

This section includes the discussion of an ATMP before a formal application for marketing authorisation is submitted. These cases refer for example to requests for an accelerated assessment for medicines that are of major interest for public health or can be considered a therapeutic innovation: in case of an accelerated assessment the assessment timetable is reduced from 210 to 150 days.

CAT contributes to the evaluation of a Paediatric Investigation Plan (PIPs) for ATMPs by the Paediatric Committee. These PIPs are included in this section of the Agenda.

ITF Briefing meeting in the field of ATMPs

This section refers to briefing meetings of the Innovation Task Force and International co-operations activities of the CAT

The Innovation Task Force (ITF) is a body set up to encourage early dialogue with applicants developing innovative medicines. Minutes of meetings with applicants developing ATMPs and of other ITF meetings of interest to the CAT are included in this section of the agenda. Further information on the ITF can be found here.

Priority Medicines (PRIME)

This section includes the new requests for eligibility to PRIME for ATMPs under development, the discussions in CAT of these eligibility requests and the final recommendations for eligibility of ATMPs adopted by CHMP.

CAT will appoint one of its members as the CAT sponsor for each new ATMP eligibility request who will lead the CAT discussion based on the recommendation from the SAWP.

Organisational, regulatory and methodological matters (section 7)

This section includes topics related to regulatory and procedural guidance, CAT workplan, CAT meeting organisation (including CAT membership), planning and reporting, co-ordination with other committees, working parties and scientific advisory groups.

Furthermore, this section refers to the activities of the CAT drafting groups developing scientific guidelines for gene therapy medicinal products and for cell-based medicinal products, cooperation within the EU regulatory network and international regulators as well as direct interaction with interested parties. It also includes topics of scientific interest for the Committee that are not directly related to the work of the CAT drafting groups or CAT associated working parties.

Any other business (section 8)

This section is populated with miscellaneous topics not suitable under the previous headings.

More detailed information on the above terms can be found on the EMA website